

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

WATKINS et al

Atty. Ref.: 620-334

Serial No. 10/509,732

Group: unknown

Filed: September 30, 2004

Examiner: unknown

For: CARBAMIC ACID COMPOUNDS COMPRISING A
PIPERAZINE LINKAGE AS HDAC INHIBITORS

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

January 7, 2005

Sir:

INFORMATION DISCLOSURE STATEMENT

- ☒ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits]
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
N/C
- ☐ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

The PTO did not receive the following
listed items (s): Some FOREIGN PAGES

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.


This paper is submitted in accordance with:

- ☒ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☐ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- ☐ a) The required Statement made in item 8 below; or
- ☐ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
- ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
- ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
- ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: _____



B. J. Sadoff

Reg. No. 36,663

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

620-334

10/509,732

APPLICANT

WATKINS et al

(Use several sheets if necessary)

FILING DATE

GROUP

September 30, 2004

unknown

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,492,394	12/2002	Billedeau et al			
	5,834,249	11/1998	Furukawa et al			

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
WO 99/02510	01/1999	WIPO			
WO 99/24399	05/1999	WIPO			
WO 00/12477	03/2000	WIPO			
WO 00/12478	03/2000	WIPO			
WO 00/37436	06/2000	WIPO			
WO 00/46221	08/2000	WIPO			
WO 00/56704	09/2000	WIPO			
WO 00/69819	11/2000	WIPO			
WO 00/69839	11/2000	WIPO			
WO 01/10834	02/2001	WIPO			
WO 01/38322	05/2001	WIPO			
WO 01/44189	06/2001	WIPO			
WO 01/62751	08/2001	WIPO			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Andrews et al. , 2000, "Anti-malarial effect of histone deacetylation inhibitors and mammalian tumour cytodifferentiating agents," <i>Int. J. Parasitol.</i> , Vol. 30, No. 6, pp. 761-768.
	Barta et al. , 2000, "Synthesis and activity of selective MMP inhibitors with an aryl backbone," <i>Bioorg. Med. Chem. Lett.</i> , Vol. 10, No. 24, pp. 2815-2817.
	Bernhard, D. et al. , 1999, "Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts," <i>FASEB J.</i> , Vol. 13, No. 14, pp. 1991-2001.
	Bernstein et al. , 2000, "Genomewide studies of histone deacetylase function in yeast," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 97, No. 25, pp. 13708-13713.
	Brehm, A., et al. , 1998, "Retinoblastoma protein recruits histone deacetylase to repress transcription," <i>Nature</i> , 1998, Vol. 391, pp. 597-601.
	Chang et al. , 2000, "Activation of the BRLF1 promoter and lytic cycle of Epstein-Barr virus by histone acetylation," <i>Nucleic Acids Res.</i> , Vol. 28, No. 20, pp. 3918-3925.
	Dangond et al. , 1998, Differential Display Cloning of a Novel Human Histone Deacetylase (HDAC3) cDNA from PHA-Activated Immune Cells," <i>Biochem. Biophys. Res. Commun.</i> , Vol. 242, No. 3, pp. 648-652.
	David, G., et al. , 1998, "Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein," <i>Oncogene</i> , Vol. 16(19), pp. 2549-2556.
	Davie, J.R. , 1998, "Covalent modifications of histones: expression from chromatic templates," <i>Curr. Opin. Genet. Dev.</i> , Vol. 8, pp. 173-178.

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

620-334

10/509,732

APPLICANT

WATKINS et al

(Use several sheets if necessary)

FILING DATE

GROUP

September 30, 2004

unknown

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
WO 01/85680	11/2001	WIPO			
WO 01/87870	11/2001	WIPO			
WO 02/22577	03/2002	WIPO			
WO 02/26696	04/2002	WIPO			
WO 02/26703	04/2002	WIPO			
WO 02/28829	04/2002	WIPO			
WO 02/30879	04/2002	WIPO			
EP 0574758	12/1993	Europe			
EP 0827742	03/1998	Europe			
EP 0684240	11/1995	Europe			
JP 10-114681	05/1998	Japan			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Desai, D., et al. , 1999, "Chemopreventive efficacy of suberanilohydroxamic acid (SAHA), a cytodifferentiating agent, against tobacco-specific nitrosamine 4-(methylnitros-amino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in female A/J mice," <u>Proceedings of the American Association for Cancer Research, Prevention/Basic Science and Clinical Studies 4</u> , Vol. 40, p. 362, Abstract No. 2396.
	Desmarits, C., et al. , 2001, Nickel-catalysed sequential amination of aryl- and heteroaryl di- and trichlorides," <u>Tetrahedron</u> , Vol. 57, p. 7657-7664.
	Emiliani, S., et al. , 1998, "Characterization of a human RPD3 ortholog, HDAC3," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 95, p. 2795-2800.
	Finnin et al. , 1999, "Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors," <u>Nature</u> , Vol. 401, pp. 188-193.
	Grozinger et al. , 1999, "Three proteins define a class of human histone deacetylases related to yeast Hda1p," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 96, pp. 4868-4873.
	Hartwig, J.F., et al. , 1999, "Room-Temperature Palladium-Catalyzed Amination of Aryl Bromides and Chlorides and Extended Scope of Aromatic C-N Bond Formation with a Commercial Ligand," <u>J. Org. Chem.</u> , Vol. 64, pp. 5575-5580.
	Hoshikawa, Y., et al. , 1994, "Trichostatin A Induces Morphological Changes and Gelsolin Expression by Inhibiting Histone Deacetylase in Human Carcinoma Cell Lines," <u>Exp. Cell. Res.</u> , Vol. 214(1), pp. 189-197.
	Hou et al. , 2001, "Binding affinities for a series of selective inhibitors of gelatinase-A using molecular dynamics with a linear interaction energy approach," <u>J. Phys. Chem. B</u> , Vol. 105, No. 22, pp. 5304-5315.

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

INFORMATION DISCLOSURE CITATION	ATTY. DOCKET NO.	SERIAL NO.
	620-334	10/509,732
(Use several sheets if necessary)	APPLICANT	
	WATKINS et al	
	FILING DATE	GROUP
	September 30, 2004	unknown

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Howe, L., et al., 1999, "Histone Acetyltransferase Complexes and Their Link to Transcription," <u>Crit. Rev. Eukaryot. Gene Expr.</u> , Vol. 9(3-4), pp. 231-243.
	Iavarone et al., 1999, "E2F and Histone Deacetylase Mediate Transforming Growth Factor β Repression of <i>cdc25A</i> during Keratinocyte Cell Cycle Arrest," <u>Mol. Cell Biol.</u> , Vol. 19, No. 1, pp. 916-922.
	Jung, M., et al., 1999, " <u>Journal of Medicinal Chemistry</u> (ACS, Washington, USA), Vol. 42, No. 22, pp. 4669-4679.
	Kao et al., 2000, "Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression," <u>Genes & Dev.</u> , Vol. 14, p. 55-66.
	Kijima et al., 1993, "Trapoxin, an Antitumor Cyclic Tetrapeptide, Is an Irreversible Inhibitor of Mammalian Histone Deacetylase*," <u>J. Biol. Chem.</u> , Vol. 268, pp. 22429-22435.
	Kim et al., 1999, "Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase," <u>Oncogene</u> , Vol. 18(15), pp. 2461-2470.
	Kim, M.S., et al., 2001 "Histone deacetylases induce angiogenesis by negative regulation of tumour suppressor genes," <u>Nature Medicine</u> , Vol 7, No. 4, pp. 437-443.
	Kimura et al., 1994, "Dual Modes of Action of Platelet-Derived Growth Factor and Its Inhibition by Trichostatin-A for DNA Synthesis in Primary Cultured Smooth Muscle Cells of Rat Aorta," <u>Biol. Pharm. Bull.</u> , Vol. 17, No. 3, pp. 399-402.
	Kitamura, K., et al., 2000, "Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid," <u>Br. J. Haematol.</u> , Vol. 108(4), pp. 696-702.
	Kouzarides, T., 1999, "Histone acetylases and deacetylases in cell proliferation," <u>Curr. Opin. Genet. Dev.</u> , Vol. 9, No. 1, pp. 40-48.
	Kuusisto et al., 2001, "Ubiquitin-Binding Protein p62 Expression is Induced during Apoptosis and Proteasomal Inhibition in Neuronal Cells," <u>Biochem. Biophys. Res. Commun.</u> , Vol. 280, No. 1, pp. 223-228.
	Kwon et al., 1998, "Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 95, pp. 3356-3361.
	Laherty, C.D., et al., 1997, "Histone Deacetylases Associated with the mSin3 Corepressor Mediate Mad Transcriptional Repression," <u>Cell</u> , Vol. 89(3), pp. 349-356.
	Lea and Tulsyan, 1995, "Discordant Effects of Butyrate Analogues on Erythroleukemia Cell Proliferation, Differentiation and Histone Deacetylase," <u>Anticancer Res.</u> , Vol. 15, pp. 879-883.

*Examiner	Date Considered
-----------	-----------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

620-334

10/509,732

APPLICANT

WATKINS et al

(Use several sheets if necessary)

FILING DATE

GROUP

September 30, 2004

unknown

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Lea et al., 1999, "Increased acetylation of histones induced by diallyl disulfide and structurally related molecules," <u>Int. J. Oncol.</u> , Vol. 2, pp. 347-352.
	Lin, R.J., et al., 1998, "Role of the histone deacetylase complex in acute promyelocytic leukaemia," <u>Nature</u> , Vol. 391(6669), pp. 811-814.
	McCaffrey et al., 1997, "Induction of γ -Globin by Histone Deacetylase Inhibitors," <u>Blood</u> , Vol. 90, No. 5, pp. 2075-2083.
	Mielnicki, L.M., et al., 1999, "Epigenetic Regulation of Gelsolin Expression in Human Breast Cancer Cells," <u>Exp. Cell. Res.</u> , Vol. 249(1), pp. 161-176.
	Nakajima et al., 1998, "FR901228, a Potent Antitumor Antibiotic, Is a Novel Histone Deacetylase Inhibitor," <u>Exp. Cell Res.</u> , Vol. 241, pp. 126-133.
	Ng, H.H. and Bird, A., 2000, "Histone deacetylases: silencers for hire," <u>Trends Biochem. Sci.</u> , Vol. 25(3), pp. 121-126.
	Niki et al., 1999, "A Histone Deacetylase Inhibitor, Trichostatin A, Suppresses Myofibroblastic Differentiation of Rat Hepatic Stellate Cells in Primary Culture," <u>Hepatology</u> , Vol. 29, No. 3, pp. 858-867.
	Onishi et al., 1996, "Antibacterial Agents That Inhibit Lipid A Biosynthesis," <u>Science</u> , Vol. 274, pp. 939-940.
	Parrish, C.A., et al., 2001, "Use of Polymer-Supported Dialkylphosphinobiphenyl Ligands for Palladium-Catalyzed Amination and Suzuki Reactions," <u>J. Org. Chem.</u> , Vol. 66, pp. 3820-3827.
	Pazin, M.J., et al., 1997, "What's up and down with histone deacetylation and transcription?," <u>Cell</u> , Vol. 89, No. 3, pp. 325-328.
	Richon et al., 1996, "Second generation hybrid polar compounds are potent inducers of transformed cell differentiation," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 93, pp. 5705-5708.
	Richon et al., 1998, "A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 95, pp. 3003-3007.
	Saito et al., 1999, "A synthetic inhibitor of histone deacetylase, MS-27-275, with marked <i>in vivo</i> antitumor activity against human tumors," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 96, pp. 4592-4597.
	Saunders, N. et al., 1999 "Histone deacetylase inhibitors as potential anti-skin cancer agents," <u>Cancer Res.</u> , Vol. 59, No. 2 pp. 399-404.
	Sonoda, H. et al., 1996, "Oxamflatin: a novel compound which reverses malignant phenotype to normal one via induction of JunD," <u>Oncogene</u> , Vol. 13, pp. 143-149.
	Spencer, V.A. and Davie, J.R., 1999, "Role of covalent modifications of histones in regulating gene expression," <u>Gene</u> , Vol. 240(1), pp. 1-12.
	Suzuki et al., 1999, "Synthesis and histone deactylase inhibitory activity of new benzamide derivatives," <u>J. Med. Chem.</u> , Vol. 42, pp. 3001-3003.

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

INFORMATION DISCLOSURE CITATION	ATTY. DOCKET NO.	SERIAL NO.
	620-334	10/509,732
(Use several sheets if necessary)	APPLICANT	
	WATKINS et al	
	FILING DATE	GROUP
	September 30, 2004	unknown

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Takahashi, I., et al, 1996, "Selective inhibition of IL-2 gene expression by trichostatin A, a potent inhibitor of mammalian histone deacetylase," <i>J. Antibiot. (Tokyo)</i> , Vol. 49, No. 5, pp. 453-457.
	Taunton, J., et al., 1996, "A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p," <i>Science</i> , Vol. 272, pp. 408-411.
	Tsuji et al., 1976, "A New Antifungal Antibiotic, Trichostatin*," <i>J. Antibiot. (Tokyo)</i> , Vol. 29, No. 1, pp. 1-6.
	Ueda, H., et al., 1994, "FR901228, a novel antitumor bicyclic depsipeptide produced by <i>Chromobacterium violaceum</i> No. 968," <i>J. Antibiot. (Tokyo)</i> , Vol. 47(3), pp. 315-323.
	Van den Wyngaert et al., "Cloning and characterization of human histone deacetylase 8," 2000, <i>FEBS</i> , Vol. 478, pp. 77-83.
	Vigushin et al., 2001, "Trichostatin A Is a Histone Deacetylase Inhibitor with Potent Antitumor Activity against Breast Cancer <i>in vivo</i> ," <i>Clin. Cancer Res.</i> , Vol. 7, No. 4, pp. 971-976.
	Warrell et al., 1998, "Therapeutic Targeting of Transcription in Acute Promyelocytic Leukemia by Use of an Inhibitor of Histone Deacetylase," <i>J. Natl. Cancer Inst.</i> , Vol. 90, pp. 1621-1625.
	Wolfe, J.P., et al., 2000a, "Scope and Limitations of the Pd/BINAP-Catalyzed Amination of Aryl Bromides," <i>J. Org. Chem.</i> , Vol. 65, pp. 1144-1157.
	Wolfe, J.P., et al., 2000b, "Simple, Efficient Catalyst System for the Palladium-Catalyzed Amination of Aryl Chlorides, Bromides, and Triflates," <i>J. Org. Chem.</i> , Vol. 65, pp. 1158-1174.
	Wong, J., et al., 1998, "Distinct requirements for chromatin assembly in transcriptional repression by thyroid hormone receptor and histone deacetylase," <i>EMBO J.</i> , Vol. 17(2), pp. 520-534.
	Yang, W.M., et al., 1996, "Transcriptional repression of YY1 is mediated by interaction with a mammalian homolog of the yeast global regulator RPD3," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 93, pp. 12845-12850.
	Yang, W.M., et al., 1997, "Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family," <i>J. Biol. Chem.</i> , Vol 272, pp. 28001-28007.
	Yoshida et al., 1995, "Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function," <i>Bioessays</i> , Vol. 17, pp. 423-430.
	Yoshida, M. and Horinouchi, S., 1999, "Inhibition of Histone Deacetylation and Signal-Dependent Nuclear Export," <i>Ann. N. Y. Acad. Sci.</i> , Vol. 886, pp. 23-36.
	Yoshida, M., Beppu, T., 1988, "Reversible arrest of proliferation of rat 3Y1 fibroblasts in both G1 and G2 phases by trichostatin A," <i>Exp. Cell. Res.</i> , Vol. 177, pp. 122-131.
	Yoshida, M., et al., 1990a, "Potent and Specific Inhibition of Mammalian Histone Deacetylase Both <i>in Vivo</i> and <i>in Vitro</i> by Trichostatin A*," <i>J. Biol. Chem.</i> , Vol. 265(28), pp. 17174-17179.
	Yoshida, M., et al., 1990b, "Structural specificity for biological activity of trichostatin A, a specific inhibitor of mammalian cell cycle with potent differentiation-inducing activity in friend leukemia cells," <i>J. Antibiot. (Tokyo)</i> , Vol. 43(9), pp. 1101-1106.

*Examiner	Date Considered
-----------	-----------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.